FTC K-Dur Case Incorrectly Defines Market, Judge Says In Ruling For Schering

Merck-Medco's decision not to separately list Schering-Plough's K-Dur on its formulary is evidence that the drug is therapeutically substitutable and competes with other versions of potassium chloride, an administrative law judge said